(Sharecast News) - Switzerland's Novartis has agreed to buy San Diageo-based biopharmaceutical firm Avidity Biosciences for $12bn in cash.
Avidity is focused on a new class of therapeutics enabling RNA delivery to muscle. Novartis said the deal will follow the separation of Avidity's early-stage precision cardiology programs.

Novartis said Avidity...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE